United States of America v. Horizon Therapeutics

CourtDistrict Court, S.D. New York
DecidedAugust 9, 2021
Docket1:20-cv-03207
StatusUnknown

This text of United States of America v. Horizon Therapeutics (United States of America v. Horizon Therapeutics) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States of America v. Horizon Therapeutics, (S.D.N.Y. 2021).

Opinion

USDC SDNY DOCUMENT UNITED STATES DISTRICT COURT ELECTRONICALLY FILED SOUTHERN DISTRICT OF NEW YORK DOC #___ DATE FILED:_ 8/9/2021 United States of America et al. ex rel. Doe, Plaintiffs, 20-cv-3207-MKV “against- ORDER DENYING MOTION TO Horizon Therapeutics PLC et al., MAINTAIN SEAL Defendants.

MARY KAY VYSKOCIL, United States District Judge: In April 2020, Plaintiff-Relator (“Relator”) filed this action under seal on behalf of the United States (the “Government”) and over thirty states pursuant to the gui tam provisions of the False Claims Act (“FCA”), 31 U.S.C. §§ 3729 et seq., and parallel state false-claim statutes. The Complaint alleges that Defendant Horizon Therapeutics PLC (“Horizon”), an Ireland-based drug manufacturer, and its subsidiaries operating in the United States (collectively, “Defendants’’) violated the FCA in connection with the marketing and sale of the gout medication Krystexxa. (See generally Compl. [ECF No. 14].) Relator is a former employee of Horizon. (/d. Jf 6, 28, 81; Mem. Law 6 [ECF No. 21].) After an eleven-month investigation, the Government and the co-plaintiff states declined to intervene in this action. On March 22, 2021, the Court signed the proposed Order submitted by the Government, requiring that the Complaint be unsealed in thirty days and authorizing service on the Defendants by Relator at that time. (Order Mar. 22, 2021 [ECF No. 18].) On April 14, 2021, Relator filed an Amended Complaint.! (Am. Compl. [ECF No. 19].) On April 20, 2021, Relator moved to maintain the seal on this case for an unspecified period of time, advising the

' The March 22 unsealing Order references a Complaint and an Amended Complaint, but at that time no Amended Complaint had been filed.

Court that it intended to voluntarily dismiss the case and that state payors had indicated that they were continuing to investigate Relator’s allegations. (Mot. Maintain Seal [ECF No. 20]; Mem. Law 2, 8–9.) On April 23, 2021, the Court denied Relator’s motion but granted a sixty-day extension of the seal on this case to June 23, 2021. (Order Apr. 23, 2021 [ECF No. 23].) On July 14, 2021, the Court entered an Order directing Relator to show cause on or before

July 28, 2021, why the seal on this case should not be lifted. (Order July 14, 2021 [ECF No. 26].) On August 6, 2021, having not received a response to the Order to Show Cause, the Court ordered that the pleadings and other documents filed in this case be unsealed. (Order Aug. 6, 2021 [ECF No. 12].) On August 9, 2021, after the public docket was unsealed on ECF pursuant to the Court’s August 6 Order, counsel for Relator contacted Chambers directly and advised the Court that it had hand delivered to the Clerk of Court a response to the Order to Show Cause and a Stipulation of Dismissal to be filed under seal. Counsel did not provide copies of these documents to Chambers, as required under the Court’s Individual Rules of Practice in Civil Cases ¶ 9.B.

In the response to the Order to Show Cause, counsel for Relator advised the Court that the state payors had concluded further investigations and declined to bring any actions under the state false claims acts. (Magnanini ¶ 5.) Counsel for Relator also requested an extension of the seal on this case. Relator expressed the same concerns raised in its April 20 motion: Defendants and others could potentially decipher Relator’s identity based the allegations of the pleadings, creating “risks to Relator’s professional reputation and blackballing that could occur should Defendants, Relator’s current employer, or any other entities or persons become aware of Relator’s whistleblowing activities with the Government.” (Magnanini Decl. ¶ 7.) Relator’s motion to extend further the seal on this case is DENIED. Under both the common law and the First Amendment, a strong presumption of public access attaches to judicial documents. See Lugosch v. Pyramid Co. of Onondaga, 435 F.3d 110, 119–20 (2d Cir. 2006). Judicial documents are those “relevant to the performance of the judicial function and useful in the judicial process.” Id. at 119 (quoting United States v. Amodeo, 44 F.3d 141, 145 (2d Cir. 1995)).

If a document is a judicial document, courts must consider whether the presumption of access is a common law right of access or a heightened “qualified First Amendment right to attend judicial proceedings and to access certain judicial documents.” Id. at 120 (quoting Hartford Courant Co. v. Pellegrino, 380 F.3d 83, 91 (2d Cir. 2004)). If the more stringent First Amendment framework applies, “[d]ocuments may be sealed if specific, on the record findings are made demonstrating that closure is essential to preserve higher values and is narrowly tailored to serve that interest.” Id. (quoting In re N.Y. Times Co., 828 F.2d 110, 113 (2d Cir. 1987)); see also Bernstein v. Bernstein Litowitz Berger & Grossmann LLP, 814 F.3d 132, 144–45 (2d Cir. 2016) (noting that sealing requires more than “[b]road and general findings” or “conclusory assertions” (quoting N.Y. Times,

828 F.2d at 116)). As an initial matter, the Complaint and Amended Complaint are judicial documents. See Bernstein, 814 F.3d at 140. As the Second Circuit has explained, “A complaint, which initiates judicial proceedings, is the cornerstone of every case, the very architecture of the lawsuit, and access to the complaint is almost always necessary if the public is to understand a court’s decision.” Id. (quoting Fed. Trade Comm’n v. Abbvie Prods. LLC, 713 F.3d 54, 62 (11th Cir. 2013)). Furthermore, the pleadings in this case trigger the presumptive right of access under both the common law and the First Amendment. See id. at 141–43. Relator fails to identify “higher values” that outweigh the presumption of public access to the pleadings in this case. “Courts generally do not find that the risk of employer retaliation outweighs the presumption of public access to documents filed in FCA actions.” United States v. UCB, Inc., No. 14-cv-2218 (TPG), 2017 WL 838198, at *2 (S.D.N.Y. Mar. 3, 2017) (collecting cases). Relator is no longer even employed by Horizon, and Relator’s concerns of industry-wide

retaliation are wholly conjectural and have been repeatedly rejected by courts. See, e.g., United States ex rel. Love v. Teach for America, Inc., No. 17-cv-2062 (KBF), 2018 WL 1156103, at *1–2 (S.D.N.Y. Feb. 21, 2018) (“Relator’s argument that disclosure may ‘have an adverse impact on his search for future employment’ and result in ‘discrimination and retaliation in the workplace’ are entirely speculative.”); United States ex rel. Littlewood v. King Pharms., Inc., 806 F. Supp. 2d 833, 842 (D. Md. 2011) (finding “no basis” to maintain seal and dismissing relator’s concerns about employer retaliation and damage to career prospects as “hypothetical”); United States ex rel. Herrera v. Bon Secours Cottage Health Servs., 665 F. Supp. 2d 782, 785–86 (E.D. Mich. 2008) (“[T]he Court does not believe that Plaintiff–Relator’s fear of retaliation by her current employer

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re New York Times Company
828 F.2d 110 (Second Circuit, 1987)
Hartford Courant Co. v. Pellegrino
380 F.3d 83 (Second Circuit, 2004)
Lugosch v. Pyramid Co. of Onondaga
435 F.3d 110 (Second Circuit, 2006)
Federal Trade Commission v. Abbvie Products LLC
713 F.3d 54 (Eleventh Circuit, 2013)
United States Ex Rel. Durham v. Prospect Waterproofing, Inc.
818 F. Supp. 2d 64 (District of Columbia, 2011)
United States v. Bon Secours Cottage Health Services
665 F. Supp. 2d 782 (E.D. Michigan, 2008)
United States v. Amodeo
44 F.3d 141 (Second Circuit, 1995)
United States ex rel. Wenzel v. Pfizer, Inc.
881 F. Supp. 2d 217 (D. Massachusetts, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
United States of America v. Horizon Therapeutics, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-of-america-v-horizon-therapeutics-nysd-2021.